H.C. Wainwright lowered the firm’s price target on Korro Bio (KRRO) to $90 from $100 and keeps a Buy rating on the shares. The firm updated the company’s model post the Q2 report to account for increases in potentially dilutive shares outstanding.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KRRO:
- Korro Bio Advances RNA Editing Programs in Q2 2025
- Korro Bio reports Q2 EPS ($2.74), consensus ($2.59)
- Buy Rating for Korro Bio Driven by Promising KRRO-110 and Orphan Drug Designation
- Korro Bio receives European Medicines Agency granted ODD for KRRO-110
- Korro Bio management to meet with Piper Sandler